Antonello Pietrangelo

Antonello Pietrangelo's AcademicInfluence.com Rankings

Physics

#5554

World Rank

#7404

Historical Rank

physics Degrees

Download Badge

Physics

Antonello Pietrangelo's Degrees

PhD Physics University of Milan
Masters Physics University of Milan
Bachelors Physics University of Milan

Why Is Antonello Pietrangelo Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Antonello Pietrangelo's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Hereditary hemochromatosis--a new look at an old disease. (2004) (937)
Tocilizumab in patients with severe COVID-19: a retrospective cohort study (2020) (758)
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism (2009) (722)
Autosomal-dominant hemochromatosis is associated with a mutation in the ferroportin (SLC11A3) gene. (2001) (565)
Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia (2020) (564)
Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment. (2010) (516)
Unravelling the Complexity of Inherited Retinal Dystrophies Molecular Testing: Added Value of Targeted Next-Generation Sequencing (2016) (334)
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. (2007) (303)
Expression of the duodenal iron transporters divalent-metal transporter 1 and ferroportin 1 in iron deficiency and iron overload. (2001) (301)
ER Stress Controls Iron Metabolism Through Induction of Hepcidin (2009) (291)
Iron regulatory proteins in pathobiology. (2000) (285)
Hereditary hemochromatosis in adults without pathogenic mutations in the hemochromatosis gene. (1999) (255)
Heterogeneity of hemochromatosis in Italy. (1998) (241)
The ferroportin disease (2014) (229)
Hepatocyte growth factor/hepatopoietin A is expressed in fat‐storing cells from rat liver but not myofibroblast‐like cells derived from fat‐storing cells (1992) (213)
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). (2003) (204)
Hemochromatosis: An endocrine liver disease (2007) (200)
Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene. (2003) (190)
The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. (2002) (179)
Antioxidant activity of silybin in vivo during long-term iron overload in rats. (1995) (168)
Duodenal metal-transporter (DMT-1, NRAMP-2) expression in patients with hereditary haemochromatosis (1999) (168)
Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)‐SMAD signaling pathway in mice (2011) (165)
The role of the iron responsive element in the control of ferroportin1/IREG1/MTP1 gene expression. (2003) (163)
Metals, oxidative stress, and hepatic fibrogenesis. (1996) (163)
Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. (2008) (160)
Regulation of transferrin, transferrin receptor, and ferritin genes in human duodenum. (1992) (155)
Haemochromatosis (2003) (151)
Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis. (2009) (149)
Wild-type HFE protein normalizes transferrin iron accumulation in macrophages from subjects with hereditary hemochromatosis. (2000) (145)
Iron, oxidative stress and liver fibrogenesis. (1998) (143)
Juvenile hemochromatosis associated with pathogenic mutations of adult hemochromatosis genes. (2005) (139)
Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. (1995) (137)
Physiology of iron transport and the hemochromatosis gene. (2002) (136)
Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. (2010) (130)
Ferroportin disease: A systematic meta-analysis of clinical and molecular findings☆ (2010) (126)
Hypoxia induced downregulation of hepcidin is mediated by platelet derived growth factor BB (2014) (121)
Response of young, aged and osteoarthritic human articular chondrocytes to inflammatory cytokines: molecular and cellular aspects. (2002) (118)
Hepcidin in human iron disorders: therapeutic implications. (2011) (118)
The ferroportin disease. (2014) (112)
Genetics, Genetic Testing, and Management of Hemochromatosis: 15 Years Since Hepcidin. (2015) (111)
Gluconeogenic Signals Regulate Iron Homeostasis via Hepcidin in Mice (2014) (106)
BMP6 treatment compensates for the molecular defect and ameliorates hemochromatosis in Hfe knockout mice. (2010) (104)
A Phase 1/2, Dose-Escalation Trial of Deferasirox for the Treatment of Iron Overload in HFE-Related Hereditary Hemochromatosis (2010) (103)
Management of chronic viral hepatitis in patients with thalassemia: recommendations from an international panel. (2010) (101)
Activin B Induces Noncanonical SMAD1/5/8 Signaling via BMP Type I Receptors in Hepatocytes: Evidence for a Role in Hepcidin Induction by Inflammation in Male Mice. (2016) (99)
Inappropriately high iron regulatory protein activity in monocytes of patients with genetic hemochromatosis. (1997) (95)
Duodenal ferritin synthesis in genetic hemochromatosis. (1995) (94)
Enhanced hepatic collagen type I mRNA expression into fat‐storing cells in a rodent model of hemochromatosis (1994) (93)
Non-HFE hepatic iron overload. (2011) (92)
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia. (2019) (89)
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (2020) (87)
Ferroportin disease: pathogenesis, diagnosis and treatment (2017) (87)
Albumin gene expression is down-regulated by albumin or macromolecule infusion in the rat. (1992) (84)
Iron and the liver (2016) (83)
EASL International Consensus Conference on Haemochromatosis (2000) (81)
POPDC1(S201F) causes muscular dystrophy and arrhythmia by affecting protein trafficking. (2016) (80)
BMP-6 is a key endogenous regulator of hepcidin expression and iron metabolism (2010) (75)
Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study (2017) (73)
Frequency and biochemical expression of C282Y/H63D hemochromatosis (HFE) gene mutations in the healthy adult population in Italy. (2001) (72)
Hemochromatosis gene modifies course of hepatitis C viral infection. (2003) (72)
Liver gene expression during chronic dietary iron overload in rats (1990) (70)
Kupffer cells and macrophages are not required for hepatic hepcidin activation during iron overload (2005) (70)
Transferrin receptor gene expression during rat liver regeneration. Evidence for post-transcriptional regulation by iron regulatory factorB, a second iron-responsive element-binding protein. (1994) (70)
Iron-induced oxidant stress in alcoholic liver fibrogenesis. (2003) (69)
C/EBP-β/LAP Controls Down-regulation of Albumin Gene Transcription during Liver Regeneration* (1996) (68)
Non‐HFE hemochromatosis (2004) (67)
Iron in NASH, chronic liver diseases and HCC: how much iron is too much? (2009) (67)
Non-HFE hemochromatosis. (2005) (67)
Mechanisms of Disease: the role of hepcidin in iron homeostasis—implications for hemochromatosis and other disorders (2004) (67)
Excess iron into hepatocytes is required for activation of collagen type I gene during experimental siderosis. (1994) (63)
HJV gene mutations in European patients with juvenile hemochromatosis (2005) (61)
Mechanism of iron toxicity. (2002) (60)
Iron and steatohepatitis (2012) (56)
Huh‐7: A human “hemochromatotic” cell line (2010) (55)
Molecular insights into the pathogenesis of hereditary haemochromatosis (2006) (54)
Serum ferritin in the assessment of liver iron overload and iron removal therapy in porphyria cutanea tarda. (1986) (53)
Iron-Induced Oxidant Stress Leads to Irreversible Mitochondrial Dysfunctions and Fibrosis in the Liver of Chronic Iron-Dosed Gerbils. The Effect of Silybin (2000) (52)
Iron removal therapy in porphyria cutanea tarda: phlebotomy versus slow subcutaneous desferrioxamine infusion (1986) (52)
Nitric-oxide-mediated activation of iron-regulatory protein controls hepatic iron metabolism during acute inflammation. (1995) (52)
Magnetic resonance imaging to identify classic and nonclassic forms of ferroportin disease. (2006) (50)
Frequency of the S65C mutation of HFE and iron overload in 309 subjects heterozygous for C282Y. (2002) (50)
Keratin variants are overrepresented in primary biliary cirrhosis and associate with disease severity (2009) (49)
Molecular and clinical correlates in iron overload associated with mutations in ferroportin. (2006) (49)
Hereditary hemochromatosis. (2006) (46)
Iron-Induced Oxidant Stress in Nonparenchymal Liver Cells: Mitochondrial Derangement and Fibrosis in Acutely Iron-Dosed Gerbils and Its Prevention by Silybin (2002) (45)
Serum Albumin Is Inversely Associated With Portal Vein Thrombosis in Cirrhosis (2019) (45)
Hepatitis B virus infection in porphyria cutanea tarda. (2008) (41)
Impaired Iron Transport Activity of Ferroportin 1 in Hereditary Iron Overload (2005) (41)
Molecular genetics and control of iron metabolism in hemochromatosis. (1998) (41)
Serum Ferritin as a Predictor of Treatment Outcome in Patients With Chronic Hepatitis C (2009) (40)
Altered hepatic BMP signaling pathway in human HFE hemochromatosis. (2010) (40)
Regulation of hepatic transferrin, transferrin receptor and ferritin genes in human siderosis (1991) (40)
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol (2020) (39)
Haptoglobin modifies the hemochromatosis phenotype in mice. (2005) (38)
Evaluating the association of serum ferritin and hepatic iron with disease severity in non‐alcoholic fatty liver disease (2019) (38)
Lipid composition and fluidity of liver mitochondria, microsomes and plasma membrane of rats with chronic dietary iron overload. (1990) (36)
Effect of heparin-like compounds on the in vitro proliferation and protein synthesis of various cell types. (1989) (36)
Iron chelation beyond transfusion iron overload (2007) (36)
Human macrophage ferroportin biology and the basis for the ferroportin disease (2017) (36)
Hepatic stellate cells are not subjected to oxidant stress during iron‐induced fibrogenesis in rodents (1998) (34)
The role of Ito cells in the biosynthesis of HGF-SF in the liver. (1993) (34)
Inherited metabolic disease of the liver (2009) (30)
Lack of enterocyte iron accumulation in the ferroportin disease. (2005) (30)
Lack of coordinate control of ferritin and transferrin receptor expression during rat liver regeneration (1998) (30)
Hepatic stellate cell nomenclature. (1996) (30)
3-Hydroxy-(4H)-benzopyran-4-ones as potential iron chelating agents in vivo. (2001) (30)
Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI) (2021) (29)
Mechanisms of iron hepatotoxicity. (2016) (29)
Hemochromatosis 1998: is one gene enough? (1998) (29)
Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. (2013) (29)
Ferroportin is a monomer in vivo in mice. (2006) (28)
Expression of messenger RNA for liver functions following 70% and 90% hepatectomy. (1996) (27)
Clinical impact of application of risk assessment models (Padua Prediction Score and Improve Bleeding Score) on venous thromboembolism, major hemorrhage and health expenditure associated with pharmacologic VTE prophylaxis: a “real life” prospective and retrospective observational study on patients h (2018) (26)
Spatial and temporal dynamics of hepatic stellate cell activation during oxidant-stress-induced fibrogenesis. (1998) (25)
Hepcidin expression does not rescue the iron-poor phenotype of Kupffer cells in Hfe-null mice after liver transplantation. (2010) (25)
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. (2021) (24)
Current challenges in the management of patients with sickle cell disease – A report of the Italian experience (2019) (24)
Prevalence of Gastrointestinal Symptoms in Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Results of the Prospective Controlled Multinational GI-COVID-19 Study (2021) (24)
The SMAD Pathway Is Required for Hepcidin Response During Endoplasmic Reticulum Stress. (2016) (23)
Disease progression and liver cancer in the ferroportin disease (2007) (23)
Incidence and Recurrence of Portal Vein Thrombosis in Cirrhotic Patients (2019) (23)
Hyperhomocysteinemia and MTHFR C677T polymorphism in patients with portal vein thrombosis complicating liver cirrhosis. (2016) (22)
Translational regulation of ferritin synthesis in rat liver. Effects of chronic dietary iron overload. (1989) (21)
Homeostatic regulation of hepatocyte nuclear transcription factor 1 expression in cultured hepatoma cells. (1994) (19)
Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad? (2020) (19)
Impact of D181V and A69T on the function of ferroportin as an iron export pump and hepcidin receptor. (2014) (19)
Standard or branched-chain amino acid infusions as short-term nutritional support in liver cirrhosis? (1985) (19)
Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency anemia (2018) (18)
Genetic iron overload disorders. (2020) (18)
Gene expression of urea cycle enzymes following two-thirds partial hepatectomy in the rat. (1995) (17)
Low Rate of Intrahospital Deep Venous Thrombosis in Acutely Ill Medical Patients: Results From the AURELIO Study (2019) (17)
Non-invasive assessment of hepatic iron overload: are we finally there? (2005) (16)
Coproporphyrin excretion in healthy newborn babies. (1984) (16)
Better prognosis in females with severe COVID-19 pneumonia: possible role of inflammation as potential mediator (2020) (16)
Pain and Frailty in Hospitalized Older Adults (2020) (15)
Iron, friend or foe? "Freedom" makes the difference. (2000) (15)
Comorbidity does not mean clinical complexity: evidence from the RePoSI register (2019) (15)
Luspatercept Increases Hemoglobin, Decreases Transfusion Burden and Improves Iron Overload in Adults with Beta-Thalassemia (2016) (15)
Clinical risk scores for the early prediction of severe outcomes in patients hospitalized for COVID-19 (2021) (14)
Pathogens, Metabolic Adaptation, and Human Diseases--An Iron-Thrifty Genetic Model. (2015) (14)
Pattern of comorbidities and 1-year mortality in elderly patients with COPD hospitalized in internal medicine wards: data from the RePoSI Registry (2020) (13)
DNA repair in lymphocytes from humans and rats with chronic iron overload. (1988) (12)
Design, synthesis, and physicochemical and biological characterization of a new iron chelator of the family of hydroxychromenes. (2002) (12)
Advances in the treatment of porphyria cutanea tarda. Effectiveness of slow subcutaneous desferrioxamine infusion. (2008) (11)
Luspatercept (ACE-536) Reduces Disease Burden, Including Anemia, Iron Overload, and Leg Ulcers, in Adults with Beta-Thalassemia: Results from a Phase 2 Study (2015) (11)
First and second waves among hospitalised patients with COVID-19 with severe pneumonia: a comparison of 28-day mortality over the 1-year pandemic in a tertiary university hospital in Italy (2022) (11)
British Association for the Study of the Liver (1991) (11)
Hyperhomocysteinemia in patients with acute porphyrias: a possible effect of ALAS1 modulation by siRNAm therapy and its control by vitamin supplementation. (2021) (11)
G80S-linked ferroportin disease: the first clinical description in a Greek family. (2008) (10)
Genetics in liver diseases. (2007) (10)
LUSPATERCEPT DECREASES TRANSFUSION BURDEN AND LIVER IRON CONCENTRATION IN REGULARLY TRANSFUSED ADULTS WITH BETA-THALASSEMIA (2016) (9)
Multicenter observational study on the reliability of the HEART score (2019) (9)
The penetrance of hemochromatosis: mice to the rescue. (2007) (8)
Hereditary hemochromatosis masquerading as rheumatoid arthritis. (2001) (8)
187 A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION TRIAL USING THE ONCE-DAILY ORAL CHELATOR DEFERASIROX TO TREAT IRON OVERLOAD IN HFE-RELATED HEREDITARY HEMOCHROMATOSIS: FINAL RESULTS (2009) (8)
A Phase I/II, Open-Label, Dose-Escalation Trial of Once-Daily Oral Chelator Deferasirox to Treat Iron Overload in HFE-Related Hereditary Hemochromatosis: Final Results of the Core Study. (2009) (7)
Juvenile Hemochromatosis, Genetic Study and Long-term Follow up after Therapy (2014) (7)
RETRACTED ARTICLE: The porphyrias: pathophysiology (2010) (7)
Association between celiac disease and idiopathic dilated cardiomyopathy: a case report (2011) (7)
Clinical and molecular epidemiology of erythropoietic protoporphyria in Italy (2020) (7)
Hemochromatosis and Hemojuvelin G320V Homozygosity in a Hungarian Woman (2010) (6)
Porphyria cutanea tarda in beta-thalassemia trait carriers. (1984) (6)
5 – Disorders of iron overload (2012) (6)
Hepcidin and iron (2015) (6)
Hepcidin Activation During Inflammation: Make It STAT (2007) (6)
Diacerhein blocks iron regulatory protein activation in inflamed human monocytes. (1998) (6)
An unfortunate case of post-ERCP complications (2017) (6)
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection (2021) (6)
Ferroportin-related haemochromatosis associated with novel Y64H mutation of the SCL40A1 gene (2014) (5)
Hyperferritinemia and diagnosis of type 1 Gaucher disease (2020) (5)
Strategies for liver support: from stem cells to xenotransplantation. (2004) (5)
Design of an Ongoing Phase I/II Open-Label, Dose-Escalation Trial Using the Oral Chelator Deferasirox To Treat Iron Overload in HFE-Related Hereditary Hemochromatosis (HH). (2007) (5)
The impact of inherited thrombophilia on liver transplantation. (2009) (5)
Lipid composition and fluidity of liver plasma membranes from rats with chronic dietary iron overload (1989) (5)
Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: The Decongestion duRing therapY for acute decOmpensated heart failure in HFpEF vs HFrEF- DRY-OFF study. (2021) (5)
ZAP-70 expression in chronic lymphocytic leukemia: a new parameter for an old disease (2003) (4)
Subclinical liver fibrosis in patients with idiopathic pulmonary fibrosis (2020) (4)
Expert Consensus Conference. The screening for hepatitis C virus infection in adults in Italy, May 5-6, 2005. (2006) (4)
Impact of natural neuromedin‐B receptor variants on iron metabolism (2019) (4)
Ursodeoxycholic Acid Complexation with 2-Hydroxypropyl-β-Cyclodextrin Increases Ursodeoxycholic Acid Biliary Excretion after Single Oral Administration in Rats (2001) (4)
Impact of Diabetes Mellitus and Its Comorbidities on Elderly Patients Hospitalized in Internal Medicine Wards: Data from the RePoSi Registry (2022) (4)
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (4)
Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (4)
Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives (2022) (4)
Metal storage disorders. Forward. (2011) (4)
Modulation of the synthesis of apolipoproteins in rat hepatoma cells. (1988) (3)
Juvenile hemochromatosis. (2006) (3)
Enhanced hepatic collagen gene expression in a rodent model of haemochromatosis (1992) (3)
Prevalence of use and appropriateness of antidepressants prescription in acutely hospitalized elderly patients. (2019) (3)
Post COVID-19 irritable bowel syndrome (2022) (3)
C/EBP- (cid:98) /LAP Controls Down-regulation of Albumin Gene Transcription during Liver Regeneration* (1996) (3)
Endothelial Dysfunction in Acute Hepatic Porphyrias (2022) (3)
Erratum: Iron overload in Africans and African-Americans and a common mutation in the SCL40A1 (ferroportin 1) gene (Blood Cells, Molecules, and Diseases (2003) 31 (299-304) DOI: 10.1016/S1079-9796(03)00164-5) (2004) (3)
The SLC11A3 gene, encoding for a main iron export protein, is controlled posttranscriptionally by iron (2002) (3)
Asymptomatic and symptomatic deep venous thrombosis in hospitalized acutely ill medical patients: risk factors and therapeutic implications (2022) (3)
Impact of COVID-19 pandemic on medication use in the older Italian population (2022) (3)
In vitro functional characterization of splicing variants of the APOB gene found in familial hypobetalipoproteinemia. (2019) (3)
A small molecule redistributes iron in ferroportin-deficient mice and patient-derived primary macrophages (2022) (3)
Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia (2022) (2)
Proteins of iron metabolism: by Ugo Testa. 608 pp. $209.95. CRC press, LLC, Atlanta, Georgia, 2001. ISBN 0849386764. Web address for ordering: www.crcpress.com (2003) (2)
Iron and the liver. (2004) (2)
Short-Term Branched Chain Amino Acid Parenteral Nutrition in Liver Cirrhosis: A Dose-Related Effect on Plasma Amino Acids and Nitrogen Balance (1984) (2)
What to start with in first line treatment of chronic hepatitis B patients: an Italian multicentre observational cohort, HBV-RER study group. (2017) (2)
Missed treatment in an Italian HBV infected patients cohort: HBV RER. (2016) (2)
VITAMIN-E SUPPLEMENTATION PREVENTS HEPATIC CIRRHOSIS DUE TO IRON OVERLOAD IN RODENTS (1993) (2)
MOLECULAR AND CELLULAR ASPECTS OF LIVER-DISEASE IN GENETIC HEMOCHROMATOSIS (1995) (2)
Is poor vitamin status a reliable target for treatment of symptomatic patients with hepatic acute porphyrias? (2019) (2)
Underdiagnosis and undertreatment of osteoporotic patients admitted in internal medicine wards in Italy between 2010 and 2016 (the REPOSI Register) (2021) (2)
Rare ceruloplasmin variants are associated with hyperferritinemia and increased hepatic iron in NAFLD patients: results from a NGS study (2018) (2)
No HFE, no HLA, no 6p-linked adult hemochromatosis: A new genetic iron overload condition (1998) (2)
Reducing the risk of hospital admission: a call to action from the Italian Society of Internal Medicine. (2015) (2)
Impact of implementing a Choosing Wisely educational intervention into clinical practice: The CW-SIMI study (a multicenter-controlled study). (2021) (2)
Studies on the regulation of liver gene expression in experimental and human siderosis (1991) (2)
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis (2017) (2)
Internists or specialists-that is the question! (2022) (2)
215 IS FLOW-MEDIATED DILATATION (FMD) ASSESSMENT A RELIABLE MARKER OF ENDOTHELIAL DYSFUNCTION IN LIVER CIRRHOSIS? (2013) (2)
Idiopathic brain calcification in a patient with hereditary hemochromatosis (2020) (2)
LUSPATERCEPT INCREASES HEMOGLOBIN, REDUCES LIVER IRON CONCENTRATION, AND IMPROVES QUALITY OF LIFE IN NON-TRANSFUSION DEPENDENT ADULTS WITH BETA-THALASSEMIA (2016) (1)
Clinical outcomes and survival in patients with hepatocellular carcinoma and HIV infection. (2010) (1)
Correction to: Hyperglycemia at admission, comorbidities, and in-hospital mortality in elderly patients hospitalized in internal medicine wards: data from the RePoSI Registry (2021) (1)
Comparison of Deferasirox, Deferiprone, and Desferrioxamine Effectiveness on Myocardial Iron Concentrations and Biventricular Function by Quantitative MR in Beta-Thalassemia Major (2008) (1)
Ataxia-Myoclonus Syndrome in Patients with SARS-CoV-2 Infection (2021) (1)
Regulation of ferroportin (SLC11A3) gene by iron (2002) (1)
Randomized, Open Label, Phase IIa Controlled Trials Evaluating the Safety of the Association of Deferasirox with Standard Antiviral Therapy (Peg-interferon and Ribavirin) in Patients with Chronic Hepatitis C (2014) (1)
Iron overload in rodents leads to hepatic cirrhosis through enhancement of collagen gene expression into non-parenchymal cells. (1994) (1)
[587] ANTIVIRAL TREATMENT PROFOUNDLY AFFECTS IRON STATUS IN HCV PATIENTS: IMPLICATIONS FOR MANAGEMENT AND TREATMENT OUTCOME (2007) (1)
4 – Disorders of Iron Overload (2018) (1)
Hereditary hemochromatosis. (2006) (1)
[Determination of serum ferritin in porphyria cutanea tarda. A reliable sign of hepatic siderosis]. (1984) (1)
Development of post-COVID-19 cardiovascular events: an analysis of clinical features and risk factors from a single hospital retrospective study. (2021) (1)
The impact of COVID-19 pandemic on well-being of Italian physicians: a report from the Italian Society of Internal Medicine (SIMI) national survey (2022) (1)
[Hereditary coproporphyria. A familial study]. (1984) (1)
[Diagnosis of digestive diseases]. (1990) (1)
Corrigendum to “Ferroportin disease: A systematic meta-analysis of clinical and molecular findings” J. Hepatol. 2010 Nov;53(5):941–949 (2011) (1)
Can Disruption of Basal Ganglia-Thalamocortical Circuit in Wilson Disease Be Associated with Juvenile Myoclonic Epilepsy Phenotype? (2022) (1)
Cross-talk between regulation of iron homeostasis and gluconeogenesis in a murine model of hereditary hemochromatosis (2020) (0)
92 THE MOLECULAR BASIS FOR THE HEPATIC REGULATION OF HEPCIDIN, THE IRON HORMONE, BY BONE MORPHOGENETIC PROTEINS (2011) (0)
Dynamics and correlates of iron biomarkers in chronic hepatitis C patients undergoing antiviral treatment: an interim report (2006) (0)
Defective control or iron metabolism in pre-neoplastic liver nodules during experimental carcinogenesis (1996) (0)
Hereditary haemochromatosis: the genes and the disease (2006) (0)
Hepatitis C virus-induced reactive oxygen species cause iron accumulation in mice by reducing hepcidin transcription (2007) (0)
Primary hypoparathyroidism is common in adult patients with [beta]-thalassemia and protect patients from osteoporosis (2015) (0)
Effect of anti-osteoarthritic drugs on interleukin 1-dependent activation of NF-kappa B in human chondrocytes (2007) (0)
Prescription appropriateness of anti-diabetes drugs in elderly patients hospitalized in a clinical setting: evidence from the REPOSI Register. (2023) (0)
SEX HORMONES DIFFERENTLY REGULATE HEPCIDIN EXPRESSION AND IRON HOMEOSTASIS IN VIVO. (2013) (0)
Fortune favours the bold: finding the right route in the anemia's sea (2016) (0)
Solving hemochromatosis with knock-out mice. (2003) (0)
Improvement of survival in patients with intermediate stage (BCLC-B) hepatocellular acrcinoma complicating liver cirrhosis by combination therapy with radiofrequency ablation and transcatheter chemioembolization (2015) (0)
An update of the genetic status of the 55 Italian hemochromatosis patients with incomplete or negative HFE genotypes (2002) (0)
Intravenous fat and glucose in liver cirrhosis (1987) (0)
Epidemiology of porphyrias in Italy: rare complex diseases with liver involvement- data from the registry of Gruppo Italiano Porfiria (GrIP) (2019) (0)
Late breaking abstracts (2005) (0)
F-28 Flow-mediated dilatation (FMD) assessment as a marker of endothelial dysfunction in liver cirrhosis (2013) (0)
Book Review Hemochromatosis: Genetics, pathophysiology, diagnosis and treatment Edited by James C. Barton and Corwin Q. Edwards. 616 pp., illustrated. New York, Cambridge University Press, 2000. $215. 0-521-593808 (2000) (0)
Studies in Hemochromatosis Type 3: How Does TfR2 Control Hepatic Hepcidin Expression? (2012) (0)
SALIVARY TYPE HYPERAMYLASEMIA IN CHRONIC LIVER-DISEASE (1985) (0)
Markers of Endothelial Dysfunction in patients with liver cirrhosis with anh without portal hypertension (2015) (0)
203 ANTIALDOSTERONE THERAPY IN LIVER CIRRHOSIS: A ROLE FOR PREVENTION OF CIRROTHIC CARDIOMIOPATHY? (2010) (0)
Esters of hyaluronic acid with the Rhine, the manufacturing processes for it and thus compositions (2005) (0)
Homeostatic control of hepatocyte nuclear transcription factor-1 activity and albumin gene expression in cultured hepatoma cells (1993) (0)
Introduction (2007) (0)
OC.06.3 POST-COVID-19 IRRITABLE BOWEL SYNDROME (2023) (0)
Clinical features and outcomes of elderly hospitalised patients with chronic obstructive pulmonary disease, heart failure or both (2023) (0)
W1848 Keratin Variants Associate with Primary Biliary Cirrhosis (2008) (0)
IRON IS A MITOGENIC AND PROFIBROGENIC FACTOR IN EXPERIMENTAL LIVER FIBROSIS DUE TO IRON OVERLOAD (1994) (0)
A PAIR OF BROTHERS WITH ACERULOPLASMINEMIA DUE TO A NOVEL NONSENSE MUTATION: UNUSUAL PHENOTYPE AND EFFECTIVENESS OF IRON-CHELATION THERAPY BY DEFERASIROX (2016) (0)
Consensus Statement on the definition and classification of metabolic hyperferritinaemia (2023) (0)
Molecular and Cellular Aspects of Iron-Mediated Liver Toxicity (1996) (0)
Sex hormones differently regulate hepatic hepcidin expression and systemic iron homeostasis in vivo (2014) (0)
Myocardial fibrosis by delayed enhancement cardiovascular magnetic resonance and HCV infection in thalassemia major patients (2010) (0)
THE BMP'S PATHWAY IN HEPCIDIN REGULATION DURING ENDOPLASMIC RETICULUM STRESS RESPONSE. (2013) (0)
Thyroid volume in adult beta-thalassemic patients is smaller than in controls (2014) (0)
AJG-21-1347 147..157 (0)
P281 GLUCONEOGENIC SIGNALS DIRECTLY CONTROL IRON HOMEOSTASIS THROUGH HEPCIDIN (2014) (0)
Authors' response to "Measuring serum hepcidin concentrations" (2005) (0)
A Pair of Brothers with Aceruloplasminemia Due To A Novel Nonsense Mutation: Unusual Phenotype And Neurological Improvement After Iron-Chelation Therapy With Deferasirox (2017) (0)
The Natural History of Ferroportin Disease – First Results of the International, Multicenter non-HFE Registry (2019) (0)
1025 MARKERS OF ENDOTHELIAL DYSFUNCTION AS PREDICTORS OF ASCITIC DECOMPENSATION IN PATIENTS WITH LIVER CIRRHOSIS (2013) (0)
Erratum to: The porphyrias: pathophysiology (2011) (0)
Clinical Questions in Iron Overload (2009) (0)
742 EFFICACY AND SAFETY OF ENTECAVIR (ETV) PROPHYLAXIS IN INACTIVE HBV CARRIERS WHO UNDERWENT CHEMOTHERAPY FOR SOLID OR HAEMATOLOGICAL CANCER: INTERIM ANALYSIS OF A COHORT STUDY (2013) (0)
The S65C mutation of HFE may contribute to iron overload in C282Y heterozygotes. (2000) (0)
HLA-H mutations in Italian patients with genetic hemochromatosis: Evidence of genetic heterogeneity (1997) (0)
Clinical application of NGS in the diagnosis of iron overload disorders or hyperferritinemia of genetic origin (2023) (0)
F-13 Efficacy and safety of combination therapy with pegylated interferon and ribavirin in aged patients with chronic hepatitis C (2012) (0)
A Fatal Case of Pseudomonas aeruginosa Community-Acquired Pneumonia in an Immunocompetent Patient: Clinical and Molecular Characterization and Literature Review (2023) (0)
THE IMPACT OF DISEASE CAUSING MUTATIONS AND BENIGN SEQUENCE VARIANTS OF FERROPORTIN ON IRON EXPORT AND HEPCIDIN RESPONSE. (2011) (0)
Relationship between Pattern of Hepatic Iron Deposition, Disease Severity and Clinical Outcomes in Non-Alcoholic Fatty Liver Disease (2016) (0)
A pediatric case report of acute intermittent porphyria: Learning the lesson (2014) (0)
Do All Critically Ill Patients with COVID-19 Disease Benefit from Adding Tocilizumab to Glucocorticoids? A Retrospective Cohort Study (2023) (0)
5 BETTER SUSTAINED CONTROL OF CHRONIC GENOTYPE 1 HCV INFECTIONS WITH PEG-IFN ALFA-2A THAN WITH PEG-IFN ALFA-2B TREATMENT: RESULTS OF DAILY CLINICAL PRACTICE (2010) (0)
Ursodeoxycholic acid complexation with 2-hydroxypropyl-beta-cyclodextrin increases ursodeoxycholic acid biliary excretion after single oral administration in rats. (1998) (0)
T-29 Serum endothelin-1 as predictor of ascitic decompensation in patients with liver cirrhosis (2013) (0)
Labile plasma iron and echocardiographic parameters are associated with cardiac events in β‐thalassemic patients (2023) (0)
Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients (2022) (0)
Transcription of the albumin gene is down regulated by albumin or macromolecule infusion in the rat (1991) (0)
T-13 Entecavir (ETV) prophylaxis in inactive HBV carriers who underwent chemotherapy for solid or haematological cancer: interim analysis of a cohort study (2013) (0)
P1070 FIRST LINE TREATMENT FOR CHRONIC HEPATITIS B (CH-B) IN REAL LIFE. AN ITALIAN MULTICENTER OBSERVATIONAL COHORT (HBV-RER) (2014) (0)
Oxidant stress: cell signalling and gene response in the liver: the iron-oxygen connection. (1998) (0)
F-11 Combination of radiofrequency ablation and transcatheter arterial chemoembolization improves survival in advanced hepatocellular carcinoma complicating liver cirrhosis (2012) (0)
30 HIV INFECTION AND SURVIVAL IN PATIENTS WITH HCC AND LIVER CIRRHOSIS (2010) (0)
Clinical and genetic characterization of autosomal dominant hereditary iron overload (2002) (0)
Treatment of chronic hepatitis C by pegylated interferon plus ribavirin combination therapy in aged patients : why not ? (2011) (0)
Mixed hepatic iron deposition but not serum ferritin is associated with the presence of nonalcoholic steatohepatitis (NASH) (2018) (0)
LBP-32-The Natural History of Ferroportin Disease-First Results of the International, Multicenter EASL non-HFE Registry (2019) (0)
Iron transporter ferroportin FPN1 (2003) (0)
British Association for the Study of the Liver Meeting (2000) (0)
An unusual dyspnea in an 87-year old woman affected by Sjögren’s syndrome (2021) (0)
Sudden Onset of Lower Abdominal Pain Without Peritonitis or Ileus (2016) (0)
MTHFR C677T polymorhism and hyperhomocysteinemia in patients with liver cirrhosis complicated by portal vein thrombosis and hepatocellular carcinoma (2009) (0)
O.65 Nutritional effects of branched chain amino acid alone and enriched parenteral solutions in liver cirrhosis (1983) (0)
PROCEEDINGS of the XVI CONGRESS OF THE ITALIAN SOCIETY OF MYOLOGY Lecce, Italy June 8-11, 2016 (2016) (0)
State-of-the-Art Lecture II: Hereditary haemochromatosis: the genes and the disease (2007) (0)
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis (2014) (0)
[Internal medicine evaluation of the surgical risk in cirrhosis patients]. (1987) (0)
P1270 SEX HORMONES DIFFERENTLY REGULATE HEPATIC HEPCIDIN EXPRESSION AND SYSTEMIC IRON HOMEOSTASIS IN VIVO (2014) (0)
foe? "Freedom" makes (2000) (0)
Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with Chronic Hepatitis B (2022) (0)
A VALIDATED ELISA FOR QUANTITATING HUMAN SERUM HEMOJUVELIN. (2013) (0)
Table of contents (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Antonello Pietrangelo?

Antonello Pietrangelo is affiliated with the following schools: